| Model: | - |
|---|---|
| Brand: | - |
| Origin: | - |
| Category: | Chemicals / Organic Chemical Materials / Pharmaceutical Chemicals |
| Label: | Relugolix API , Relugolix |
| Price: |
-
|
| Min. Order: | - |
| Last Online:28 Apr, 2023 |
| ame | Relugolix,CAS 737789-87-6 |
| Other names | 737789-87-6;
TAK-385; TAK 385; UNII-P76B05O5V6; 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea; CHEMBL1800159; P76B05O5V6; Orgovyx; 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea; Relugolix [USAN:INN]; TAK385; TAK-385/TAK385; Relugolix (JAN/INN); Relugolix(TAK-385); SCHEMBL778416 |
| Key words | AOMXMOCNKJTRQP-UHFFFAOYSA-N;
API; Relugolix uses |
| CAS number | 737789-87-6 |
| Molecular Formula | C29H27F2N7O5S |
| Molecular Weight | 623.63g/mol |
| Chemical and Physical Properties | |
| Appearance | White powder |
| Melting point | 228°C |
| Solubility | Soluble in DMSO |
| Quality standard | 99% |
| Application | |
| Drug Indication/Application/Use | Treat prostatic cancer |
| Formulations/Preparations | Tablets |
| Handling and Storage | |
| Safety and Hazards | The shanghai Research Institute of Chemical industry testing center identification conclusion :1 None hazard identification, 2 The substance is not subject to IATA DGR, 3 Non packing requirements. |
| Handling and Storage | Under inert gas (nitrogen or Argon) at 2-8°C |
| Sample package | Double plastic bags inside, aluminum foil bag outside |
| Commercial package | Double plastic bags inside,5kg, 10kg, 25kg fiber drum outside. |
| UN Code | Not classified |
| HS Code | 000000000 |
| Shipping group | Shipment at ambient temperature for no controlled and no dangerous goods |
| Sales restriction | No |
| Origin | China |
| Technnical support | |
| Relugolix,STD Data sheet
Relugolix,MSDS Relugolix,COA Relugolix,Transport Certificate |
Yes
Yes Yes Yes |
| Related APIs | 1-[4-[1-[(2,6-Difluorophenyl)methyl]-5-(methylaminomethyl)-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea;
1-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[[2-methoxyethyl(methyl)amino]methyl]-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl]phenyl]-3-ethylurea; 1-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[[2-methoxyethyl(methyl)amino]methyl]-2,4-dioxo-3-pyridin-2-ylthieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea; 1-[4-[5-[[Benzyl(ethyl)amino]methyl]-1-[(2,6-difluorophenyl)methyl]-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea; 1-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[[2-methoxyethyl(methyl)amino]methyl]-3-(4-methoxyphenyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea; 1-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[[2-ethoxyethyl(methyl)amino]methyl]-2,4-dioxo-3-pyridin-2-ylthieno[2,3-d]pyrimidin-6-yl]phenyl]-3-ethylurea |
| Supply ability | |
| Monthly capacity | / |
| GMP | Yes |
